SCHEMBL689277

SCHEMBL689277

N#Cc1cccc(OC(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.48
FFAR1 O14842 1/20 0.47
EPAS1 Q99814 2/20 0.45
ADORA1 P30542 2/20 0.45
ADORA2A P29274 1/20 0.45
TRPA1 O75762 1/20 0.44
SCN5A Q14524 1/20 0.44
SCN9A Q15858 1/20 0.44
VEGFA P15692 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
CETP P11597 1/20 0.41
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
KAT6A Q92794 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29478762 1.00 GRM5 (0.48) GRM5FFAR1EPAS1ADORA1ADORA2A
SCHEMBL923011 0.93 EPAS1 (0.47) GRM5FFAR1EPAS1ADORA1ADORA2A
SCHEMBL921695 0.88 EPAS1 (0.46) GRM5FFAR1EPAS1TRPA1SCN5A
SCHEMBL28301440 0.85 EPAS1 (0.45) GRM5EPAS1VEGFASLC6A2SLC6A4
SCHEMBL16447550 0.82 MRGPRX4 (0.50) FFAR1CETP
SCHEMBL1476671 0.82 GRM5 (0.50) GRM5FFAR1ADORA1ADORA2ATRPA1
SCHEMBL1993677 0.81 PGR (0.44) EPAS1ADORA1ADORA2ATRPA1SCN5A
SCHEMBL5733556 0.81 EPAS1 (0.42) FFAR1EPAS1ADORA1ADORA2AVEGFA
SCHEMBL921728 0.81 SCN9A (0.49) FFAR1ADORA1ADORA2ATRPA1SCN5A
SCHEMBL12296289 0.81 PTPN5 (0.54) TRPA1SCN5ASCN9ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113412113-B Amino oxazinamides 豪夫迈·罗氏有限公司 2024-07-26 CN claimed
CN-113024530-B Isatin-1, 2, 4-oxadiazole compound and preparation method and application thereof 合肥工业大学 2023-07-18 CN claimed
US-11063297-B2 Electrochemical cell and electrolyte for same Viking Power Systems Pte, Ltd. (SG) 2021-07-13 US claimed
CN-113024530-A Isatin-1, 2, 4-oxadiazole compound and preparation method and application thereof 合肥工业大学 2021-06-25 CN claimed
US-20190198933-A1 ELECTROCHEMICAL CELL AND ELECTROLYTE FOR SAME PELLION TECHNOLOGIES INC. (US) 2019-06-27 US claimed
US-20190198932-A1 ELECTROCHEMICAL CELL AND ELECTROLYTE FOR SAME PELLION TECHNOLOGIES INC. (US) 2019-06-27 US claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
EP-4735423-A1 KV7 MODULATORS Saniona A/S (DK) 2026-05-06 EP disclosed
US-20250002452-A1 BICYCLOPENTANE DERIVATIVES ANGELINI PHARMA S.P.A. (IT) 2025-01-02 US disclosed
WO-2025003343-A1 KV7 MODULATORS SANIONA A/S (DK) 2025-01-02 WO disclosed
EP-4479377-A1 NEW BICYCLOPENTANE DERIVATIVES Icagen, LLC (US) 2024-12-25 EP disclosed
CN-113412113-B Amino oxazinamides 豪夫迈·罗氏有限公司 2024-07-26 CN disclosed
US-11981686-B2 Urea compound having substituent DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-05-14 US disclosed
WO-2004062665-A1 HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS SB PHARMCO PUERTO RICO INC (US) 2004-07-29 WO disclosed
WO-1998023155-A1 ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-06-04 WO disclosed
EP-0836384-A1 ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-04-22 EP disclosed
WO-1997000612-A1 ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1997-01-09 WO disclosed
US-4148923-A 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity SYNTHELABO (FR) 1979-04-10 US disclosed
US-4129598-A ANOREXIGENIC AGENTS SYNTHELABO (FR) 1978-12-12 US disclosed
US-3965190-A ANOREXIGENIC SYNTHELABO (FR) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002452-A1 BICYCLOPENTANE DERIVATIVES BICRA, C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 GRM5 3773/4885FFAR1 1482/4885EPAS1 3993/4885
US-11981686-B2 Urea compound having substituent SIRT6, SIRT1, SIRT2 GRM5 3940/4885FFAR1 1217/4885EPAS1 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.